{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer%2C+Metastatic&page=4", "query": { "condition": "Gastrointestinal Cancer, Metastatic", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 2346, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer%2C+Metastatic&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer%2C+Metastatic&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T06:45:18.977Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06586957", "title": "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Solid Tumor, Adult", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Triple Negative Breast Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small Cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3964", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 238, "start_date": "2024-09-19", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586957" }, { "nct_id": "NCT00003951", "title": "DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "1999-06", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • San Antonio, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003951" }, { "nct_id": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Urothelial Carcinoma (UC)", "Solid Tumor", "Hepatocellular Carcinoma (HCC)", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Drug-Drug Interaction (DDI)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "DDI Probe Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1394, "start_date": "2021-12-14", "completion_date": "2030-06-28", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176483" }, { "nct_id": "NCT01847495", "title": "Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "CyberKnife", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-10", "completion_date": "2017-11-29", "has_results": false, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847495" }, { "nct_id": "NCT01064622", "title": "Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Hydrocortisone/Placebo", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 118, "start_date": "2009-09-03", "completion_date": "2013-01-31", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 25, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064622" }, { "nct_id": "NCT04906382", "title": "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lynch Syndrome", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Mismatch Repair Deficiency", "Recurrent Endometrial Cancer", "Metastatic Endometrial Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Floor Backes, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2021-07-01", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906382" }, { "nct_id": "NCT01494324", "title": "Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "CT guided percutaneous ablation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2009-10-27", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494324" }, { "nct_id": "NCT00277303", "title": "Study of XL999 in Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "XL999", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphony Evolution, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2005-12", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2010-02-22", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 8, "location_summary": "Greenbrae, California • Jacksonville, Florida • Port Saint Lucie, Florida + 5 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00277303" }, { "nct_id": "NCT02368886", "title": "Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Colorectal Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Clobetasol Propionate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2015-03-27", "completion_date": "2023-03-02", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02368886" }, { "nct_id": "NCT03098550", "title": "A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2017-06-15", "completion_date": "2020-07-06", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-10-04T06:45:18.977Z", "location_count": 5, "location_summary": "Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03098550" } ] }